Saturday, October 31, 2026

LendingTree Soars 12% Higher: Why Investors Are Buzzing

ViaNews Editorial Team

December 15, 2023

LendingTree Soars 12% Higher: Why Investors Are Buzzing

(VIANEWS) - Underlying all this activity lies a need to expand our market presence by engaging new accounts in emerging sectors such as aerospace.

About LendingTree

LendingTree, Inc. operates an online consumer platform in the US through its subsidiary LT Intermediate Company LLC. Their core business focuses on three areas: Home Loans, Consumer Lendings and Insurance Products. Home offers purchase and refinancing mortgages, reverse mortgages, home equity loans and real estate brokerage services; while consumer offers credit cards, personal and auto loans, deposit accounts and various forms of credit products including repair/settlement services. The Insurance segment provides tools, access to insurance quote products and connects consumers with lead aggregators in order to secure insurance offers. LendingTree operates marketplaces for insurance comparison and personal finance analysis as well as an investing and banking platform offering personal investment accounts, IRAs and banking services to consumers. Established in 1996 with its headquarters located in Charlotte North Carolina.

Yearly Analysis

As a financial expert, I have reviewed LendingTree's stock data and provided my opinion as follows. Please keep in mind that my analysis is solely based on what is provided and should not be seen as financial advice. LendingTree (LTREE) stock currently trades at EUR29.77, significantly below its 52-week high of EUR47.82 but higher than its 52-week low of EUR10.12. This indicates a dramatic decrease in value over the last year as market conditions improve; yet there remains potential for future growth if market conditions improve further. LendingTree's sales growth forecast for this year stands at negative 31.6%, reflecting a decrease in revenue. But next year is estimated at 4.7% growth - providing investors with important information regarding companies with strong growth potential. LendingTree currently boasts an EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) score of 1.08. This metric measures operating performance and gives insight into a company's ability to generate profits; an optimistic EBITDA indicates a company earning more money than it spends, while negative figures imply otherwise. Overall, LendingTree stock may present an attractive investment opportunity for investors willing to accept moderate risk. With its current low price and promising growth prospects, its attractive potential makes LendingTree an appealing candidate among companies with significant growth prospects. Investors should carefully consider all risks involved before making any decisions in regards to investing. They may wish to seek advice from an advisor when making any financial decisions involving stocks such as these.

Technical Analysis

LendingTree stock has seen an exceptional surge, trading well above both its 50-day and 200-day moving averages. Furthermore, its recent volume was 47.55% higher than its usual level - signalling strong buying interest in the market. But LendingTree stock's volatility has also increased, with intraday variation averages standing at 0.40%, 2.07%, and 3.75% in recent weeks, months, and quarters, respectively. Furthermore, its highest amplitude of average volatility was recorded as 2.35% for last week, 3.62% in previous months, and 3.75% during Q4. Even with its fluctuation, LendingTree's stock has been classified by a reliable indicator like the stochastic oscillator as overbought (>=80), suggesting it could be time for correction soon. Overall, investors in LendingTree should monitor its volatility and be ready for potential corrections while also keeping in mind the stock's long-term prospects and overall market conditions.

Quarter Analysis

Based on this information, LendingTree appears to have an uncertain investment outlook. While its sales growth estimates for both quarters are negative, their year-on-year quarterly revenue growth has declined by 34.8% which may cause concern; however, positive growth estimates for the next quarter could signal that management anticipates an improvement in financial performance and may warrant further investigation before making decisions based on these facts. Investors should carefully consider this information and perform extensive research prior to making any investment decisions based on this information.

Equity Analysis

LendingTree's negative EPS and ROE numbers suggest it has not been profitable over the last year, which may cause investors to worry. While ROE may measure profitability relative to shareholder's equity rather than overall, past performance does not always indicate future results, so investors should also take other factors such as growth prospects and competitive positioning into consideration before making their investment decision.

More news about LendingTree (TREE).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com